A Study Of Homoeopathic Medicine SOLIDAGO VIRGAUREA With Computer Simulation And Clinical Evaluation Of The Same In The Management Of UTERINE FIBROID .

Decoding The Therapeutic Potentials of Homoeopathic Medicine SOLIDAGO VIRGAUREA in UTERINE FIBROID:An In Silico And Randomized Clinical Approach - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086223

Enrollment

Registered

2025-05-02

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D259- Leiomyoma of uterus, unspecified

Interventions

Intervention1: Solidago Virgaurea : Solidago Virgaurea 6C in 40 size globules 3 globules thrice a day for 5 weeks Control Intervention1: Homoeopathic Constitutional medicne: constitutional medicine g

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with signs and symptoms of Uterine fibroid 2.Patients of uterine fibroid with USG findings. 3.Women of age 20-60 4.Fibroid size upto 7cm

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women 2. Patients with serious complicated systemic illness like malignancy,malignant hypertension etc 3. Fibroid cases with severe anemia Hb less than 7 g/dl 4. Complications of fibroid like torsion that need immediate surgical management 5. Patients with Extra- uterine fibroid, wandering fibroid,polyp, cervical fibroid and any fibroid causing hydronephrosis, ovarian tumors. 6. Immunocompromised individual

Design outcomes

Primary

Measure	Time frame
1. IN SILICO STUDY Identification of phytochemical compound in solidago virgaurea on target protein of uetrine fibroid with more binding energy. 2. CLINICAL STUDY 2A- changes in the Uterine Fibroid Symptom by baseline UFS-QOL (uterine fibroid symptom and health related quality of life) questionnaire and final UFS-QOL questionnaire. 2B- Reducing the size and number of uterine fibroid in transvaginal or abdominal USG by Baseline USG and Final USGTimepoint: 1. IN SILICO STUDY DURATION;minimum of 1 month 2. CLINICAL STUDY 2A-UFS-QOL Questionnaire INTERVAL:3 week 2B-USG DURATION:6 months	—

Measure

Time frame

1. IN SILICO STUDY Identification of phytochemical compound in solidago virgaurea on target protein of uetrine fibroid with more binding energy. 2. CLINICAL STUDY 2A- changes in the Uterine Fibroid Symptom by baseline UFS-QOL (uterine fibroid symptom and health related quality of life) questionnaire and final UFS-QOL questionnaire. 2B- Reducing the size and number of uterine fibroid in transvaginal or abdominal USG by Baseline USG and Final USGTimepoint: 1. IN SILICO STUDY DURATION;minimum of 1 month 2. CLINICAL STUDY 2A-UFS-QOL Questionnaire INTERVAL:3 week 2B-USG DURATION:6 months

—

Secondary

Measure	Time frame
Comparison of Therapeutic effectiveness of Solidago virgaurea and constitutional medicine among the group. Timepoint: After 1 Year (after completion of the study)	—

Countries

India

Contacts

Public ContactDr Ramseena P

Government Homoeopathic Medical College Karaparamba Kozhikode

drjayakishan@gmail.com9446529775

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026